The S100A9 inhibitor tasquinimod already demonstrated both efficacy and a favorable toxicity profile in castrate-resistant prostate cancer (NCT01732549, NCT01234311) and might offer an alternative and safer approach to disturb the cancer cell metabolism. Here, S100A9 is linked to prostate cancer.